Clinical and hematologic features
| Characteristic . | Quantity . |
|---|---|
| Patients, no. | 214 |
| Median age, y (range) | 72 (27-94) |
| Male:female ratio (%) | 138:76 (65) |
| Median MDS duration, y (range) | 2.2 (0.0-12.9) |
| Median RBC units/8 wk (range) | 4.0 (1-24) |
| Patients receiving 2 or more RBC units/mo | 139 (65) |
| IPSS risk category | |
| Low | 92 (43) |
| Intermediate-1 | 76 (36) |
| Intermediate-2/high | 8 (4) |
| Unclassified | 38 (18) |
| FAB type | |
| RA | 47 (22) |
| RARS | 86 (40) |
| RAEB | 24 (11) |
| CMML | 20 (9) |
| RAEB-t | 5 (2) |
| AML | 1 (1) |
| Inadequate specimen | 31 (14) |
| Neutropenia (< 1.5×109/L) | 57 (27) |
| Thrombocytopenia (< 100×109/L) | 41 (20) |
| Characteristic . | Quantity . |
|---|---|
| Patients, no. | 214 |
| Median age, y (range) | 72 (27-94) |
| Male:female ratio (%) | 138:76 (65) |
| Median MDS duration, y (range) | 2.2 (0.0-12.9) |
| Median RBC units/8 wk (range) | 4.0 (1-24) |
| Patients receiving 2 or more RBC units/mo | 139 (65) |
| IPSS risk category | |
| Low | 92 (43) |
| Intermediate-1 | 76 (36) |
| Intermediate-2/high | 8 (4) |
| Unclassified | 38 (18) |
| FAB type | |
| RA | 47 (22) |
| RARS | 86 (40) |
| RAEB | 24 (11) |
| CMML | 20 (9) |
| RAEB-t | 5 (2) |
| AML | 1 (1) |
| Inadequate specimen | 31 (14) |
| Neutropenia (< 1.5×109/L) | 57 (27) |
| Thrombocytopenia (< 100×109/L) | 41 (20) |
Data are numbers of patients (%) unless otherwise indicated.